Effect of nisoldipine (BAY k 5552) on methacholine-induced bronchoconstriction in patients with nonspecific bronchial hyperreactivity.
The purpose of this study was to determine whether a new calcium antagonist, nisoldipine (BAY k5552), exerted protection against methacholine-induced bronchoconstriction in subjects with hyperreactive airways. Twelve symptomless rhinitic and/or asthmatic patients with previously demonstrated bronchial hyperreactivity to methacholine were treated with placebo or nisoldipine (10 mg) according to a randomized, double-blind, crossover, placebo-controlled study design. Airway reactivity was examined through changes in response to methacholine challenge three hours after drug or placebo administration. Nisoldipine, in comparison to placebo, produced a weak but significant rise of provocative dose of methacholine responsible for a 15% fall in FEV1 (P less than .01). The data suggest that a single dose of 10 mg of nisoldipine is able partially to counteract methacholine-induced bronchoconstriction in atopic subjects with nonspecific airway hyperresponsiveness.
Verdiani
P
P
Division of Pneumology, G A Pizzetti Hospital, Grosseto, Italy.
Di Carlo
S
S
Baronti
A
A
D001249:Asthma / Q000188:drug therapy / Q000503:physiopathology; D001980:Bronchi / Q000187:drug effects* / Q000503:physiopathology; D001985:Bronchial Provocation Tests; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D006801:Humans; D016210:Methacholine Chloride; D008688:Methacholine Compounds; D015737:Nisoldipine / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012130:Respiratory Hypersensitivity / Q000188:drug therapy* / Q000503:physiopathology; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy / Q000503:physiopathology
D008688:Methacholine Compounds; D016210:Methacholine Chloride; D015737:Nisoldipine